Patent intelligence · WO
WO 2022081033
OPICAPONE ET LÉVODOPA POUR LE TRAITEMENT DE LA MALADIE DE PARKINSON
OPICAPONE ET LÉVODOPA POUR LE TRAITEMENT DE LA MALADIE DE PARKINSON
Patent details — WO 2022081033
- Jurisdiction
- WO
- Status
- granted
- Grant date
- Apr 21, 2022
- Expiration
- Apr 16, 2042
- Applicant
- BIAL PORTELA & Cª S A [PT]
- CPC classes
- A61K 31/ 165 A I, A61K 31/ 198 A I, A61K 31/ 4439 A I, A61K 45/ 06 A I
Quick answer
WO 2022081033 (OPICAPONE ET LÉVODOPA POUR LE TRAITEMENT DE LA MALADIE DE PARKINSON) is held by BIAL PORTELA & Cª S A [PT]. Status: granted. Granted Apr 21, 2022. Expires Apr 16, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- BIAL PORTELA & Cª S A [PT]
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61K 31/ 165 A I, A61K 31/ 198 A I, A61K 31/ 4439 A I, A61K 45/ 06 A I, A61K/31165, A61K/31198
More from BIAL PORTELA & Cª S A [PT]
Related pharmaceutical patents in our USPTO index.
-
WO 2022025781
DISPERSION SOLIDE D'OPICAPONE
granted -
WO 2021182981
OPICAPONE MICRONISÉE
granted -
WO 2020246903
INHIBITEURS DE DOPAMINE-B-HYDROXYLASE
granted -
AU 2018379646
Dopamine-B-hydroxylase inhibitors
granted -
BR PI0923819
compostos farmacêuticos
granted -
EP 3515433
DIE BLUT-HIRN-SCHRANKE PASSIERENDE DOPAMIN-B-HYDROXYLASE-INHIBITOREN
granted -
US 2019008774
PHARMACEUTICAL FORMULATIONS COMPRISING NITROCATECHOL DERIVATIVES AND METHODS OF MAKING THE SAME
granted
Frequently asked questions
What is US patent 2022081033?
WO 2022081033 (OPICAPONE ET LÉVODOPA POUR LE TRAITEMENT DE LA MALADIE DE PARKINSON) is held by BIAL PORTELA & Cª S A [PT]. Status: granted. Granted Apr 21, 2022. Expires Apr 16, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.
Who owns WO 2022081033?
BIAL PORTELA & Cª S A [PT] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 21 pharmaceutical patents for this assignee.
When does WO 2022081033 expire?
Our index shows an expiration date of Apr 16, 2042 (16 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.